Cheng-Kai Kao, MD, is an academic hospitalist board-certified in clinical informatics. In addition to clinical practice and residency education, his areas of interest in informatics include clinical decision support systems, documentation improvement, clinical pathways, mobile health, and healthcare innovation. As Chief Medical Information Officer, he leads multiple initiatives that leverage information technology to provide decision support for the frontline clinicians to ensure patient safety, optimize clinical workflow to increase work efficiency, enhance usability of the electronic health record system to reduce screen time, and make innovations to improve care quality and patient experience. He is the course instructor of clinical informatics at Pritzker School of Medicine and master program of biomedical informatics at University of Chicago.
Dr. Kao also serves as the medical director in the office of international programs. He oversees the clinical course of international patients from all over the world, optimizes their care quality and patient experience, promotes the knowledge transfer service, and fosters collaboration with overseas academic medical centers and healthcare organizations.
Dr. Kao is also the site principal investigator of several phase III clinical trials on novel oral anticoagulants, one of which led to the FDA approval of the new oral anticoagulant. Dr. Kao is named Top Hospitalist by American College of Physicians Hospitalist magazine in 2017.
CLINICAL LEADERSHIP
Medical Director, Office of International Programs, University of Chicago Medicine (2014-present)
Medical Director of Informatics, University of Chicago Medicine (2014-2017)
Associate Chief Medical Information Officer, University of Chicago Medicine (2017-2022)
Chief Clinical Informatics Innovation Officer (2022-)
EDUCATION ACTIVITIES
Course Director, ‘Leadership and Innovation’ and ‘Decision Support Systems and Health Care,’ Master of Science in Biomedical Informatics (MScBMI), University of Chicago Graham School
Course Director, ‘Building the Business Plan,’ Certificate in the Business of Biotechnology Program, University of Chicago Graham School
Course Director, ‘Overview of Medical Informatics’, Medical Student 4th Year Elective, University of Chicago Pritzker School of Medicine
National Library of Medicine
Georgia
- Biomedical Informatics
2016
University of Chicago Booth School of Business
Chicago
- D4Lab Fellowship
2013
Oregon Health and Science University
Oregon
- AMIA 10x10
2012
Albert Einstein Medical Center
Philadelphia
Residency - Internal Medicine
2011
National Taiwan University
Taiwan
MD - Medicine
2006
Implementation of a Real-Time Documentation Assistance Tool: Automated Diagnosis (AutoDx).
Implementation of a Real-Time Documentation Assistance Tool: Automated Diagnosis (AutoDx). Appl Clin Inform. 2024 May; 15(3):501-510.
PMID: 38701857
A crowdsourced campaign in IT optimization to improve ease of practice.
A crowdsourced campaign in IT optimization to improve ease of practice. J Hosp Med. 2023 12; 18(12):1144-1147.
PMID: 37753838
Use of clinical pathways integrated into the electronic health record to address the coronavirus disease 2019 (COVID-19) pandemic.
Use of clinical pathways integrated into the electronic health record to address the coronavirus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol. 2023 02; 44(2):260-267.
PMID: 35314010
Reducing Inpatient Hypoglycemic Events: A Focus on Mealtime Insulin.
Reducing Inpatient Hypoglycemic Events: A Focus on Mealtime Insulin. Clin Diabetes. 2022; 40(3):366-369.
PMID: 35983427
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20; 379(12):1118-1127.
PMID: 30145946
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. J Am Heart Assoc. 2017 Jul 11; 6(7).
PMID: 28698258
Consumer Mobile Health Apps: Current State, Barriers, and Future Directions.
Consumer Mobile Health Apps: Current State, Barriers, and Future Directions. PM R. 2017 May; 9(5S):S106-S115.
PMID: 28527495
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. Am Heart J. 2017 Mar; 185:93-100.
PMID: 28267480
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation. 2017 02 14; 135(7):648-655.
PMID: 27881569
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016 08 11; 375(6):534-44.
PMID: 27232649
American College of Physician Top Hospitalist
ACP Hospitalist
2017
Excellent Practical Training Award of Internship
National Taiwan University
2006
Student Service Education Award
National Taiwan University
2006
Outstanding College Youth
National Taiwan University
2005
Presidential Award
National Taiwan University
2004
Gold Medal
International Chemistry Olympiad
1999